Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults.

Horowitz MP, Milanese C, Di Maio R, Hu X, Montero LM, Sanders LH, Tapias V, Sepe S, van Cappellen WA, Burton EA, Greenamyre JT, Mastroberardino PG.

Antioxid Redox Signal. 2011 Aug 15;15(4):855-71. doi: 10.1089/ars.2010.3629. Epub 2011 Jun 6.

2.

Redox sensitivity of tyrosine hydroxylase activity and expression in dopaminergic dysfunction.

Di Giovanni G, Pessia M, Di Maio R.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):419-29. Review.

PMID:
22483306
3.

Dopaminergic neurons.

Chinta SJ, Andersen JK.

Int J Biochem Cell Biol. 2005 May;37(5):942-6. Epub 2004 Dec 2. Review.

PMID:
15743669
4.

Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.

Liang CL, Wang TT, Luby-Phelps K, German DC.

Exp Neurol. 2007 Feb;203(2):370-80. Epub 2006 Sep 28.

PMID:
17010972
5.

Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.

Proença MB, Dombrowski PA, Da Cunha C, Fischer L, Ferraz AC, Lima MM.

Neuropharmacology. 2014 Jan;76 Pt A:118-26. doi: 10.1016/j.neuropharm.2013.08.024. Epub 2013 Sep 4.

PMID:
24012539
6.

Mesencephalic type I astrocytes mediate the survival of substantia nigra dopaminergic neurons in culture.

O'Malley EK, Sieber BA, Black IB, Dreyfus CF.

Brain Res. 1992 Jun 5;582(1):65-70.

PMID:
1379874
8.

Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.

Perier C, Bender A, García-Arumí E, Melià MJ, Bové J, Laub C, Klopstock T, Elstner M, Mounsey RB, Teismann P, Prolla T, Andreu AL, Vila M.

Brain. 2013 Aug;136(Pt 8):2369-78. doi: 10.1093/brain/awt196.

PMID:
23884809
9.
10.

Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.

Norazit A, Meedeniya AC, Nguyen MN, Mackay-Sim A.

Brain Res. 2010 Nov 11;1360:119-29. doi: 10.1016/j.brainres.2010.08.070. Epub 2010 Aug 31.

PMID:
20807515
11.

Substantia nigra control of basal ganglia nuclei.

Guatteo E, Cucchiaroni ML, Mercuri NB.

J Neural Transm Suppl. 2009;(73):91-101. Review.

PMID:
20411770
12.

Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?

Ziv I, Offen D, Barzilai A, Haviv R, Stein R, Zilkha-Falb R, Shirvan A, Melamed E.

J Neural Transm Suppl. 1997;49:195-202. Review.

PMID:
9266428
13.

The role of glial cells in Parkinson's disease.

Vila M, Jackson-Lewis V, Guégan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S.

Curr Opin Neurol. 2001 Aug;14(4):483-9. Review.

PMID:
11470965
14.
16.

A dibenzoylmethane derivative protects dopaminergic neurons against both oxidative stress and endoplasmic reticulum stress.

Takano K, Kitao Y, Tabata Y, Miura H, Sato K, Takuma K, Yamada K, Hibino S, Choshi T, Iinuma M, Suzuki H, Murakami R, Yamada M, Ogawa S, Hori O.

Am J Physiol Cell Physiol. 2007 Dec;293(6):C1884-94. Epub 2007 Oct 3.

17.
18.

G protein-coupled inward rectifier modulated by dopamine agonists in cultured substantia nigra neurons.

Kim KM, Nakajima Y, Nakajima S.

Neuroscience. 1995 Dec;69(4):1145-58.

PMID:
8848103
19.
20.

Adult neurogenesis and Parkinson's disease.

Arias-Carrión O, Freundlieb N, Oertel WH, Höglinger GU.

CNS Neurol Disord Drug Targets. 2007 Oct;6(5):326-35. Review.

PMID:
18045161

Supplemental Content

Support Center